The importance of miRNAs and epigenetics in acute lymphoblastic leukemia prognosis.


Journal

Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222

Informations de publication

Date de publication:
04 2019
Historique:
received: 05 01 2018
accepted: 25 01 2018
pubmed: 1 2 2018
medline: 17 3 2020
entrez: 1 2 2018
Statut: ppublish

Résumé

Acute lymphoblastic leukemia (ALL), one of the most common malignant human disorders, originates in different important genetic lesions in T-cell or B-cell progenitors. ALL is a malignant lymphoid progenitor with peak prevalence in children (2-5 years). The rate of survival when one is suffering from ALL depends on various agents including the age of the patient, responses to anti-leukemic therapy, and cell biology. miRNAs and epigenetics are important regulatory factors in the expression of genes. miRNAs are noncoding RNA with inhibitory effectors on specific mRNA. Patterns of DNA methylation are profoundly changed in ALL by epigenetic mechanisms. The deciphering of miRNA and the epigenetic pathogenesis in ALL could revolutionize response to the therapy and outcome, and create an enormous promise for novel approaches to reduce the toxic side-effects of intensive leukemia. Hence, pathogenetic miRNAs and epigenetics leading to the initiation and the progression of ALL are summarized in this review.

Identifiants

pubmed: 29384211
doi: 10.1002/jcp.26510
doi:

Substances chimiques

Biomarkers, Tumor 0
MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3216-3230

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Reza Ranjbar (R)

Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Ansar Karimian (A)

Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Cancer & Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Student Research Committee, Babol University of Medical Sciences, Babol, Iran.

Arad Aghaie Fard (A)

Faculty of Medical Science, Department of Hematology, Tarbiat Modares University, Tehran, Iran.

Mehdi Tourani (M)

Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Maryam Majidinia (M)

Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran.

Farhad Jadidi-Niaragh (F)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Bahman Yousefi (B)

Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH